Beyfortus 50 MG/0.5 ML syringe 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDB2T
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $40,718
Award facts
- Contract value 100% obligated
- $40,717.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 22, 2026, the Defense Logistics Agency awarded a delivery order valued at $40,717.77 to AmerisourceBergen Drug Corp for the supply of Beyfortus (nirsevimab) 50 mg/0.5 mL syringes. This firm fixed-price delivery order, with an ultimate completion date of January 23, 2026, represents a pediatric respiratory syncytial virus (RSV) immunization product to support federal medical supply requirements. The award was made on a competitive, non-set-aside basis to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, which serves as a critical vendor for military and federal healthcare systems. The parent company, Cencora, Inc. (doing business as AmerisourceBergen), holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 31, 2031, which serves as the overarching vehicle for comprehensive pharmaceutical and medical supply delivery to support global military healthcare programs.
This delivery order falls under the broader DLA pharmaceutical procurement framework that supplies essential medications and vaccines across multiple therapeutic domains to military treatment facilities and federal healthcare institutions. AmerisourceBergen's extensive federal contracting experience and established relationship with the Defense Logistics Agency position it as a qualified vendor for specialized pharmaceutical products required by the Defense Health Agency and other government healthcare systems. The rapid completion timeline reflects the urgent procurement nature of this immunization product, which is used to provide respiratory syncytial virus protection for eligible infants and young children within the military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FDB2T?
SPE2DR26FDB2T was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FDB2T worth?
The government has obligated $40,718 on SPE2DR26FDB2T.
Is contract SPE2DR26FDB2T an order under another contract?
Yes. SPE2DR26FDB2T is a delivery order under SPE2DR25D1100, an indefinite delivery contract.
Was contract SPE2DR26FDB2T competed?
The extent of competition for SPE2DR26FDB2T was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award